Team:LMU-Munich/Team/Collaborations

From 2014.igem.org

(Difference between revisions)
(Results:)
(Results:)
Line 85: Line 85:
         },
         },
{name: 'error bars',
{name: 'error bars',
-
type: errorbar,
+
type: 'errorbar',
data: [[200,207],[169881.6,19113.7],[448.5,614.2],[3116.3,4530.4]]
data: [[200,207],[169881.6,19113.7],[448.5,614.2],[3116.3,4530.4]]
}]
}]

Revision as of 14:00, 12 October 2014

Collaborations

Collaborations and the exchange of knowledge were important aspects during our iGEM participation. Therefore we had a intensive collaboration with the iGEM team Groningen (Netherlands) and laid a high priority on the exchange with the Rathenau Institute also located in the Netherlands. In addition we also took part in the Interlab Study of this year´s iGEM competition.

Interlab Study

Background:

The aim of the Interlab study was to evaluate three devices consisting of different Anderson promoters fused to GFP in two different backbones: pBS1C3 and pBS3K3. The devices were distributed by iGEM and the flourescence evaluation method was free of choice. For more details check: Interlab Study@iGEM

The devices:

  • Device one: BBa_I20260 consisting of J23101-B0032-E0040-B0015 in the backbone pBS3K3
Status: ready for evaluation
  • Device two: BBa_J23101 + BBa_E0240 in the backbones pBS1C3
Status: cloning before evaluation
  • Device three: BBa_J23115 + BBa_E0240 in the backbones pBS1C3
Status: cloning before evaluation

The cloning:

Devices two and three were built from their individual parts. By digesting the promotors (BBa_J23101and BBa_J23115) with SpeI-HF and PstI-HF restriction enzymes the backbone was cut open. The XbaI and PstI-HF digested GFP (BBa_E0240) was then ligated behind the promotors. After that both devices were transformed into DH5α, plated out on chloramphenicol [35mg/µl] LB-agar plates and tested via colony-PCR to identify positive clones. For clarification PCR-positive clones were sequenced: BBa_J23101 + BBa_E0240.txt BBa_J23115 + BBa_E0240.txt

Flow through cytometry analysis:

For one measurement 50 µl of an overnight culture was first incubated together with 1 µl FM4-64 at 37°C to later on identify life/dead cells. After that 1 µl of each sample was diluted in 200 µl phosphate buffered saline solution and then evaluated by flow through cytometry. In order to generate meaningful results the described measurement was perfomed three times with technical replicas. For complete details please check our Interlab study submission: LMU-Munich Interlab form

Results:



Discussion:





Collaboration with Team Groningen

A proposal of the German iGEM Teams concerning Intellectual Property

During the meetup of the German iGEM teams from 23rd to 25th May also a workshop took place in which amongst others we discussed the topic of bioethics. Moral questions were addressed, regarding the value of life and human influence on it, as well as questions dealing with the possible socioeconomic effects of synthetic biology.

Especially the topic of an open source vs. patent controlled field accounted for a large part of the discussion. During the discussion one student brought up the point that the legal status of parts in registry remains unclear and that there are parts (e.g. [http://parts.igem.org/Part:BBa_K180009 BBa_K180009]) where only upon a closer look it becomes clear that the rights are company–owned. The issue that the legal status of parts in the registry remains uncertain is also mentioned in a recent article published by Nature ([http://www.nature.com/news/synthetic-biology-cultural-divide-1.15149 Bryn Nelson ‘Synthetic Biology: Cultural Divide ’, Nature 509, 152–154, 08 May 2014]) :

"[N]o one can say with any certainty how many of these parts are themselves entirely free of patent claims."

We, the German iGEM teams, therefore like to suggest the addition of a new feature to the parts registry:

A dedicated data field of license information for each BioBrick part.

For the implementation, we propose to introduce two new fields to BioBrick part entries in the registry:

  1. A string property "LicenseInfo"
  2. A traffic light property (grey, green, yellow, red) to indicate the level of legal protection (unknown, BPA-like, free for research purposes, heavily protected)


[File:TU-BS_Part_licence_info.png]

Implementing this feature would in our opinion further clarify and extend the parts info, provide a machine-readable format and thus improve future entries. With the emerging Entrepreneurship track and applications getting closer to industrial realization, the legal status becomes more and more important. Also it would raise awareness to the topic of the legal status of parts, leading to a debate which could further promote the idea of open source. At the same time we hope that examination of most parts will show that they are indeed free of restrictive legal protections.

The German iGEM Teams,

Aachen Berlin Bielefeld-CeBiTec Braunschweig Freiburg Goettingen Hannover Heidelberg LMU-Munich Marburg Saarland Tuebingen TU Darmstadt

Collaboration with Team Virginia

   
    
        
    
     
    
        



Hi there!

Welcome to our Wiki! I'm BaKillus, the pathogen-hunting microbe, and I'll guide you on this tour through our project. If you want to learn more about a specific step, you can simply close the tour and come back to it anytime you like. So let's start!

What's the problem?

First of all, what am I doing here? The problem is, pathogenic bacteria all around the world are becoming more and more resistant against antimicrobial drugs. One major reason for the trend is the inappropriate use of drugs. With my BaKillus super powers, I want to reduce this misuse and thus do my part to save global health.

Sensing of pathogens

To combat the pathogenic bacteria, I simply eavesdrop on their communication. Bacteria talk with each other via quorum sensing systems, which I use to detect them and trigger my responses.

Adhesion

The more specific and effective I can use my powers, the lower the danger is of provoking new resistance development. So I catch pathogens whenever I get hold of them and stick to them until my work is done.

Killing

Talking about my work - killing pathogens is finally what I am made for. In response to quorum sensing molecules of the pathogens, I export a range of antimicrobial substances leading to dissipation of biofilms and the killing of the targeted bacteria.

Suicide switch

When the job is done and all the bad guys are finished, you don't need a super hero anymore. So after fulfilling my work I say goodbye to the world by activating my suicide switch.

Application

Of course I'm not only a fictional hero, but a very real one. In two different prototypes, I could be used for diagnosis or treatment of pathogen-caused diseases. However, there is still a whole lot of regulational and economical questions that have to be answered before.

See you!

So now you know my short story - and it is time for me to return to my fight for a safer world. Feel free to take a closer look on my super powers, the process of my development or the plans for a medical application.